Literature DB >> 21208364

Therapeutic potential of purinergic signalling for diseases of the urinary tract.

Geoffrey Burnstock1.   

Abstract

This review begins with background information about the discovery and conceptual steps contributing to our current knowledge of purinergic signalling. It then deals with several topics concerned with the physiology and pathophysiology of the lower urinary tract, including: the involvement in the voiding reflex of ATP released as a co-transmitter with acetylcholine from parasympathetic nerves supplying the bladder and ATP released from urothelial cells during bladder distension to initiate the voiding reflex via P2X₃ receptors on suburothelial low-threshold sensory nerve fibres; this latter mechanosensory transduction pathway is also involved via high-threshold fibres in the initiation of pain. Treatment of prostate and bladder cancer with ATP not only appears to be effective against the primary tumours, but also improves the systemic symptoms associated with advanced malignancy. There is dual control of the tone of blood vessels: constriction by ATP released as a co-transmitter from sympathetic nerves and vasodilatation via ATP released from endothelial cells during shear stress acting on endothelial P2 receptors to release nitric oxide. A purinergic hypothesis is discussed for the mechanism underlying acupuncture, widely used for the treatment of urinary disorders.
© 2011 THE AUTHOR. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21208364     DOI: 10.1111/j.1464-410X.2010.09926.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  28 in total

1.  Discovery of purinergic signalling, the initial resistance and current explosion of interest.

Authors:  G Burnstock
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Effect of short-term androgen deficiency on bladder contractility and urothelial mediator release.

Authors:  Giselle Bravo; Helen Massa; Roselyn Rose'Meyer; Russ Chess-Williams; Catherine McDermott; Donna J Sellers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-11       Impact factor: 3.000

3.  Recovery of urothelial mediator release but prolonged elevations in interleukin-8 and nitric oxide secretion following mitomycin C treatment.

Authors:  Sung Hyun Kang; Russ Chess-Williams; Shailendra Anoopkumar-Dukie; Catherine McDermott
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-03       Impact factor: 3.000

4.  Alterations in peripheral purinergic and muscarinic signaling of rat bladder after long-term fructose-induced metabolic syndrome.

Authors:  Shiu-Dong Chung; Chiang-Ting Chien; Hong-Jeng Yu
Journal:  Eur J Nutr       Date:  2012-03-18       Impact factor: 5.614

5.  The role of P2X7 purinergic receptors in inflammatory and nociceptive changes accompanying cyclophosphamide-induced haemorrhagic cystitis in mice.

Authors:  J P Martins; R B M Silva; R Coutinho-Silva; C M Takiya; A M O Battastini; F B Morrone; M M Campos
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 6.  Receptors, channels, and signalling in the urothelial sensory system in the bladder.

Authors:  Liana Merrill; Eric J Gonzalez; Beatrice M Girard; Margaret A Vizzard
Journal:  Nat Rev Urol       Date:  2016-03-01       Impact factor: 14.432

7.  Enhanced urothelial ATP release and contraction following intravesical treatment with the cytotoxic drug, doxorubicin.

Authors:  Sung-Hyun Kang; Catherine McDermott; Stefanie Farr; Russ Chess-Williams
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-17       Impact factor: 3.000

8.  Urine: Waste product or biologically active tissue?

Authors: 
Journal:  Neurourol Urodyn       Date:  2018-02-21       Impact factor: 2.696

9.  2',3'-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents.

Authors:  Diego Dal Ben; Anna Marchenkova; Ajiroghene Thomas; Catia Lambertucci; Andrea Spinaci; Gabriella Marucci; Andrea Nistri; Rosaria Volpini
Journal:  Purinergic Signal       Date:  2016-10-18       Impact factor: 3.765

10.  NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.

Authors:  Liliana Rockenbach; Elizandra Braganhol; Fabrícia Dietrich; Fabrício Figueiró; Manoella Pugliese; Maria Isabel Albano Edelweiss; Fernanda Bueno Morrone; Jean Sévigny; Ana Maria Oliveira Battastini
Journal:  Purinergic Signal       Date:  2014-01-26       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.